Immune Cells, if Rendered Insensitive to Transforming Growth Factorbeta, Can Cure Prostate Cancer
Abstract
The objective of the current proposal is to perform immunotherapy to eradicate prostate cancer and at the same time to avoid the development of autoimmune disease. The proposal contains two tasks. The first task is a combination of IL-2 based tumor-reactive T cell adoptive therapy with the TGF-beta based gene therapy for the treatment of mouse prostate cancer. The second task is A tetracycline inducible TGF-beta based gene therapy. At the time of this report, we have completed Task 1 and three papers have been published. (Cancer Research 65:1761-1769, 2005; Prostate 66:235-247, 2006; Molecular Cancer Therapeutics 5:1733-1743, 2006). Currently, we are in the process of to conduct the final phase of the studies described in Task 2.
Document Details
- Document Type
- Technical Report
- Publication Date
- Feb 01, 2007
- Accession Number
- ADA463756
Entities
People
- Chung Lee
Organizations
- Northwestern University